Suchergebnisse - "Oluwole, Olalekan O"

PubPharm (65)

1

Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies

enthalten in: Expert review of anticancer therapy | 2024

von Oluwole, O. | Neelapu, S. | Ray, M. | +5

2

Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma in the United States

enthalten in: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research | 2024

von Oluwole, O. | Ray, M. | Rosettie, K. | +5

3

Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma : outcomes by metabolic tumor volume

enthalten in: Blood | 2024

von Locke, F. | Oluwole, O. | Kuruvilla, J. | +12

4

Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids

enthalten in: Bone marrow transplantation | 2024

von Oluwole, O. | Forcade, E. | Muñoz, J. | +23

5

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

enthalten in: Blood | 2024

von Neelapu, S. | Chavez, J. | Sehgal, A. | +23

CommentIn: Blood. 2024 Feb 8;143(6):475-476. - PMID 38329775

6

Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

enthalten in: Blood advances | 2024

von Ghobadi, A. | Munoz, J. | Westin, J. | +13

7

Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting : An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

enthalten in: Transplantation and cellular therapy | 2024

von Oluwole, O. | Dholaria, B. | Knight, T. | +12

8

Chimeric Antigen Receptor T Cell Therapy for Myeloma : Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

enthalten in: Transplantation and cellular therapy | 2024

von Anderson, L. | Dhakal, B. | Jain, T. | +5

9

Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States : incorporating longer survival results

enthalten in: Journal of medical economics | 2024

von Oluwole, O. | Ray, M. | Davies, N. | +4

10

An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States

enthalten in: Journal of medical economics | 2024

von Oluwole, O. | Patel, A. | Vadgama, S. | +6

1
2
3
4
5
6
7
Nächster »
[7]